The world’s leading health organizations supporting celiac disease awareness and education (Celiac Disease Foundation, American Celiac Disease Alliance, Celiac Sprue Association, Gluten Intolerance Group and the National Foundation for Celiac Awareness) applaud the efforts of Alvine Pharmaceuticals and AbbVie in addressing the significant unmet medical need for therapeutic treatment of celiac disease. ALV003 is an investigational oral therapy composed of two recombinant, gluten specific enzymes (a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP)), that degrade gluten in-vitro and in human clinical testing, and may reduce the symptoms and intestinal injury associated with celiac disease in patients attempting to adhere to a gluten-free diet.
5/14/2013
Progress Toward Oral Therapy for Celiac Disease
Recent Posts
- New Hope for Celiac Disease: Promising Drug Shows Progress in Clinical Trials
- Clinical Trials & Celiac Disease: Learn From A Patient's Experience
- A New Study Sheds Light On The Economic Burden Of Celiac Disease Beyond The Gluten-Free Diet
- Join Us! Celiac Disease Foundation Congressional District Days 2024 Campaign
Search the archive
Categories
- Advocacy News
- Celiac Disease in the News
- Clinical Trials
- Eat! Gluten-Free
- Featured
- Foundation Press
- iCureCeliac
- Marilyn’s Message
- Monthly eNewsletter
- Patient Profile Advocacy Series
- Research News
- Research Press
- Trending Topics
Marilyn's Message
5/1/2024
Read moreRevolutionizing Celiac Disease Diagnosis – Marilyn’s Message May 2024
Celiac Disease Foundation CEO Joins a Study Developing a Breakthrough Screening Tool The Celiac Disease Foundation asks patient families to participate in research every single day. Why? Because joining research studies and clinical trials is the only way to help scientists better understand this autoimmune disease and ultimately find a...